Dasatinib Dose Optimization Based on Therapeutic Drug Monitoring in Patients with Chronic-Phase Chronic Myeloid Leukemia
TDM-based dose optimization could lead to beneficial clinical outcomes for patients with CML-CP. Furthermore, in terms of blood drug concentration, our findings supply additional evidence supporting the first-line treatment regimen of 50 mg daily.
Authors
- Zheng Cui (ORCID: https://orcid.org/0000-0003-1703-666X)
- Fang Cheng (ORCID: https://orcid.org/0000-0003-2257-6847)
- Weiming Li (ORCID: https://orcid.org/0000-0001-6276-1989)
- Liu Wang (ORCID: https://orcid.org/0000-0003-4812-0506)
- Qiang Li (ORCID: https://orcid.org/0000-0002-9815-4432)
- Yu Zhang (ORCID: https://orcid.org/0000-0003-3630-9002)
Institutions
- Union Hospital (HK)
- Wuhan Union Hospital (CN)
- Union Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Drug Design Development and Therapy
- Published
- 2025-05-01
- DOI
- https://doi.org/10.2147/dddt.s521260
- Citations
- 3
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 5.31
Funders
- Chinese Pharmaceutical Association